- XPOVIO® is the first XPO1 inhibitor approved for
reimbursement by South Korea's
National Health Insurance Service (NHIS) for the treatment of
adult patients with relapsed/refractory multiple myeloma
(R/R MM).
- The approval of XPOVIO® by the NHIS in
South Korea is the fourth national
reimbursement in the Antengene markets after mainland of
China, Australia and Singapore.
- Additional reimbursements of XPOVIO® in APAC
markets are expected.
- Antengene has also submitted the new drug applications
(NDAs) in additional ASEAN markets, including Thailand, Malaysia and Indonesia, where approvals are expected in the
H2 of 2024.
SHANGHAI and HONG KONG, June 26,
2024 /PRNewswire/ -- Antengene Corporation Limited
("Antengene", SEHK: 6996.HK), a leading innovative,
commercial-stage global biopharmaceutical company dedicated to
discovering, developing and commercializing first-in-class and/or
best-in-class medicines for cancer, today announced that
South Korea's National Health
Insurance Service (NHIS) has approved the reimbursement of
XPOVIO® (selinexor) for the treatment of adult patients
with relapsed or refractory multiple myeloma (R/R MM).
XPOVIO® will be officially
included into the national reimbursed drugs list of South Korea on July
1, 2024.
![Logo (PRNewsfoto/Antengene Corporation Limited) Logo (PRNewsfoto/Antengene Corporation Limited)](https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg)
MM, the second most common hematologic malignancy, is caused by
the dysregulated proliferation of plasma cells. Patients with MM
face a range of challenges including a high relapse rate, short
survival, and limited treatment options. According to market data,
the global MM market has exceeded US$17
billion in 2023 and is expected to reach US$ 26 billion by 2028, with a compound annual
growth rate (CAGR) of 8.7%[1].
With a novel mechanism of action, XPOVIO® is the
world's first approved orally-available, selective XPO1 inhibitor.
XPOVIO® has a global commercial presence with approvals
in over 40 countries and regions.
To date, XPOVIO® has already been included for health
insurance coverage in mainland of China, Australia and Singapore in the APAC markets. With the latest
approval from the NHIS in South
Korea, XPOVIO® is poised to be a novel treatment
option and will bring clinically meaningful survival benefits to
more patients in need.
Antengene has already submitted NDAs for XPOVIO® in
Thailand, Malaysia and Indonesia for the treatment of patients with
R/R MM and R/R diffuse large B-cell lymphoma (R/R DLBCL).
About XPOVIO® (selinexor)
XPOVIO® is the world's first approved
orally-available, selective inhibitor of the nuclear export protein
XPO1. It offers a novel mechanism of action, synergistic
effects in combination regimens, fast onset of action, and durable
responses.
By blocking the nuclear export protein XPO1, XPOVIO®
can promote the intranuclear accumulation and activation of tumor
suppressor proteins and growth regulating proteins, and
down-regulate the levels of multiple oncogenic proteins.
XPOVIO® delivers its antitumor effects through three
mechanistic pathways: 1) exerting antitumor effects by inducing the
intranuclear accumulation of tumor suppressor proteins; 2) reducing
the level of oncogenic proteins in the cytoplasm by inducing the
intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone
sensitivity by activating the glucocorticoid receptors (GR)
pathway. To utilize its unique mechanism of actions,
XPOVIO® is being evaluated for use in multiple
combination regimens in a range of indications. At present,
Antengene is conducting multiple clinical studies of
XPOVIO® in the mainland of China for the treatment of relapsed/refractory
hematologic malignancies and solid tumors (3 of these studies are
being jointly conducted by Antengene and Karyopharm Therapeutics
Inc. [Nasdaq:KPTI]).
About Antengene
Antengene Corporation Limited ("Antengene", SEHK:
6996.HK) is a leading commercial-stage R&D-driven global
biopharmaceutical company focused on the discovery, development,
manufacturing and commercialization of innovative
first-in-class/best-in-class therapeutics for the treatment of
hematologic malignancies and solid tumors, in realizing its vision
of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets
at various stages going from clinical to commercial, including 6
with global rights, and 3 with rights for the APAC region. To date,
Antengene has obtained 29 investigational new drug (IND) approvals
in the U.S. and Asia, and
submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for
XPOVIO® (selinexor) already approved in Mainland of
China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.
Forward-looking statements
The forward-looking statements made in this article relate only
to the events or information as of the date on which the statements
are made in this article. Except as required by law, we undertake
no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise, after the date on which the statements are made or to
reflect the occurrence of unanticipated events. You should read
this article completely and with the understanding that our actual
future results or performance may be materially different from what
we expect. In this article, statements of, or references to, our
intentions or those of any of our Directors or our Company are made
as of the date of this article. Any of these intentions may alter
in light of future development. For a further discussion of these
and other factors that could cause future results to differ
materially from any forward-looking statement, please see the other
risks and uncertainties described in the Company's Annual Report
for the year ended December 31, 2023,
and the documents subsequently submitted to the Hong Kong Stock
Exchange.
Reference:
[1] Global Multiple Myeloma Treatment
Market Size, Share & Trends Analysis Report by Treatment Type
(Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell
Transplantation), by Region, and Segment Forecasts, 2023-2028.
For more information, please contact:
Investor Contacts:
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158
PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000
View original content to download
multimedia:https://www.prnewswire.com/news-releases/antengene-announces-xpovio-selinexor-national-health-insurance-service-approval-for-reimbursement-in-south-korea-302182936.html
SOURCE Antengene Corporation Limited